Dong-E-E-Jiao Co.,Ltd. (000423.SZ): BCG Matrix [Apr-2026 Updated]

Dong-E-E-Jiao's portfolio reads like a classic transformation story: high-ROI stars-premium Ejiao liquids, snacks, instant powders and digital exclusives-are driving rapid growth and commanding significant CAPEX to scale, while the traditional Ejiao block and B2B raw-materials act as mighty cash cows (42% revenue) funding expansion; several question-mark bets in beauty, tonics and fermented drinks need targeted investment to become the next stars, and a handful of low-growth dogs (legacy generics, donkey breeding, low-end liquors, generic gift boxes) are ripe for divestment or outsourcing to free capital for growth channels. Continue to see how management's allocation choices will shape market leadership and margin sustainability.

Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - BCG Matrix Analysis: Stars

Stars

The following sections detail the company's Star business units-high market growth, high relative market share-across clinical, consumer, convenience and digital channels, with key metrics on revenue contribution, market growth, market share, CAPEX intensity and ROI.

Fufang Ejiao Jiang clinical expansion is a core Star: contributing 32% of corporate revenue in 2025, growing at 18% annually due to NRDL inclusion and expanded Grade‑A hospital prescriptions. The segment holds a 24% share in the blood‑enriching TCM liquid category. CAPEX is elevated at 12% of segment revenue to scale production and fund clinical trials and evidence‑based marketing. Estimated ROI is 26%, driven by prescription volume, brand premium and hospital channel margins.

• Revenue contribution: 32% of total company revenue (2025).
• Market growth: 18% p.a. post‑NRDL inclusion.
• Market share: 24% in category.
• CAPEX intensity: 12% of segment revenue.
• ROI: ~26%.

Ejiao Plus health snack diversification (Peach Blossom Cake and related SKUs) achieved a 15% revenue share in 2025. It participates in a functional food market expanding at 22% annually, driven by Guochao and Gen Z demand. Gross margin stands at 58%, with a premium positioning that supports an 18% market share in the premium TCM snack subcategory. Marketing CAPEX remains high at 15% of sales to sustain social commerce and influencer‑led campaigns, supporting rapid share gains and high lifetime value customers.

• Revenue share: 15% (2025).
• Market growth: 22% p.a.
• Market share: 18% premium TCM snacks.
• Gross margin: 58%.
• Marketing CAPEX: 15% of sales.

The Instant Ejiao powder convenience series shows a 28% year‑on‑year sales volume increase through December 2025, contributing 10% of total company revenue. The product attains a 20% market share in modern TCM formats and a 65% gross margin. Targeted investment in specialized low‑temperature extraction technology raised segment CAPEX by 8% to secure product quality and scale capacity. Current ROI is approximately 22%, reflecting strong price elasticity and repeat purchase behavior among urban professionals.

• Revenue contribution: 10% of total revenue.
• Sales volume growth: +28% YoY (2025).
• Market share: 20% in modern TCM format.
• Gross margin: 65%.
• CAPEX: +8% for extraction tech; ROI ~22%.

Digital channel exclusive health products are expanding rapidly with 35% growth and now account for 14% of company revenue. These SKUs capture 12% of the online TCM supplement marketplace and operate with a 25% operating margin. Dong‑E‑E‑Jiao allocates roughly 10% of its operational budget to digital supply chain enhancements (fulfillment, data analytics, logistics) to sustain this channel's scalability. The reduced physical retail overhead and direct consumer data integration yield a high ROI of approximately 30%.

• Revenue share: 14% of total revenue.
• Online portfolio growth: 35% (2025).
• Market share: 12% online TCM supplements.
• Operating margin: 25%.
• Operational budget allocation: 10% to digital supply chain.
• ROI: ~30%.

Aggregate Star portfolio metrics: combined Stars contribute 71% of 2025 revenue (32% + 15% + 10% + 14% = 71%), operate across market growth rates of 18-35%, maintain category market shares of 12-24%, and require segment CAPEX intensity ranging from 8% to 15% with ROIs between 22% and 30%, and gross margins up to 65% where applicable.

Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - BCG Matrix Analysis: Cash Cows

Cash Cows

The Traditional Ejiao Block market dominance remains the primary cash-generating unit for Dong-E-E-Jiao. In fiscal 2025 the flagship Ejiao Block accounted for 42% of total company revenue, delivering a gross margin of 74% and a dominant 62% share of the national Ejiao block market. Market growth for this mature product is approximately 5% annually. Capital expenditures allocated to this product line are minimal at 3% of its revenue, while net cash flow generated by the segment exceeds RMB 2.0 billion in 2025, providing the liquidity base for R&D and portfolio diversification.

The B2B Bulk Ejiao raw material supply business supplies professional-grade donkey-hide gelatin to pharmaceutical partners and accounts for 8% of total company revenue. As of late 2025 this segment holds a 55% market share within the professional TCM ingredient sector. Market expansion is limited (c.3% growth annually), but the unit produces an 18% ROI and maintains gross margins near 45% owing to vertical control of the donkey-hide supply chain. CAPEX is restricted to approximately 2% of segment revenue, focused on quality control and traceability systems rather than capacity expansion.

Royal Jelly and honey products operate as a stable ancillary cash cow, contributing 5% to consolidated sales in 2025. The product line occupies roughly a 12% market share within its mature segment and grows at about 4% annually. Gross margins average 40% and ROI is approximately 15%. Production assets are largely fully depreciated, permitting CAPEX needs of about 1% of revenue for maintenance only. Net cash contribution is steady and supports dividend policy and short-term working capital.

The Traditional Ejiao syrup legacy line, positioned in the cough-and-tonic liquid category, provided 6% of company revenue in 2025 and held an estimated 15% market share in that category. The market growth rate is low (~2% annually). The line sustains a gross margin of 52% and an ROI near 20%, with negligible CAPEX and modest marketing spend (<2% of corporate marketing budget). Longstanding brand equity and pharmacy distribution networks make this unit a predictable liquidity source.

Key operational and financial characteristics of the cash cow portfolio:

• High aggregated gross margin concentration driven by Ejiao Block (weighted average gross margin for cash cows ~60%+).
• Low aggregate CAPEX intensity across cash cows (weighted CAPEX <3% of cash cow revenues), enabling strong free cash flow conversion.
• Conservative market growth (2-5% range) consistent with mature TCM categories; stability over expansion.
• Dominant market shares in core segments (Ejiao Block 62%, bulk raw 55%) underpin pricing power and supply-chain leverage.
• Cash generation capacity (RMB >2bn from Ejiao Block alone) funds diversification, marketing for stars/question marks, and shareholder returns.

Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - BCG Matrix Analysis: Question Marks

Dogs - Question Marks: High-end TCM beauty and skincare, Deer Antler and premium tonics, Probiotic and Ejiao fermented drinks, Mens health and vitality supplements are currently low-share, variable-growth businesses in Dong-E-E-Jiao's portfolio that require focused investment decisions to determine whether they can scale to Stars or should be harvested/divested.

The newly launched high-end TCM beauty and skincare line targets a functional beauty market expanding at 25% annually. Current contribution to company revenue: 3.0%. Relative market share is low in a fragmented category. R&D allocation for 2025: 18% of total R&D spend. Gross margin: 60%. Customer acquisition costs are high, producing a neutral ROI at present. Target addressable market (China functional skincare): RMB 160 billion. Success metrics hinge on increasing channel penetration, improving repeat purchase (target 30% 12‑month repurchase rate), and achieving at least a 5-8% market share within 3-4 years to justify further scaling.

Deer Antler and premium tonics are positioned as non‑Ejiao premium health tonics. Current revenue share: 2.0%. Segment annual growth rate: 12%. Company market share: <5% in a niche dominated by regional specialists. CAPEX allocation: 10% directed to sourcing and specialized processing facilities to guarantee authenticity. Gross margin: 48%. Brand‑building investment required to achieve national recognition and scale through premium distribution. Path to Star: leverage existing premium distribution, increase marketing intensity, and secure supply chain exclusivity to reach ≥10% segment share over 4 years.

The probiotic and Ejiao fermented drinks are in pilot stage in tier‑one cities. Current revenue contribution: <1% of total revenue. Market growth rate for the beverage category targeted: 15% p.a. Market share: ~0.5% (negligible). CAPEX invested in 2025: RMB 50 million for specialized fermentation equipment. High marketing spend required to create/educate a consumption category; current ROI negative. Gross margin potential: 55%. Strategic importance lies in first‑mover advantage if consumer acceptance and distribution scale can be established; break‑even scenario requires attaining ≥3-4% market share in urban premium beverage channels over 2-3 years.

The mens health and vitality supplements line is a new venture with 1.5% revenue contribution. Segment growth: 10% p.a. Company market share: <3%. CAPEX allocation: 7% of total CAPEX to product development and regulatory approvals. Gross margin: 50%. Competitive landscape: strong incumbents including international supplement brands. Key performance triggers: achieving ≥5% market share within two fiscal years or demonstrating accelerating unit economics (customer LTV/CAC ratio >3) to warrant additional investment.

Consolidated snapshot of these Question Marks:

Recommended near‑term strategic options (conditioned on performance metrics):

• Prioritize marketing ROI and CAC reduction for TCM beauty; scale distribution into 2,000+ premium outlets and target 30% repeat purchase within 12 months.
• Invest brand equity and supply authentication for Deer Antler to reach ≥10% niche share; maintain 10% CAPEX for processing capacity.
• Continue pilot for probiotic Ejiao drinks with phased CAPEX deployment; require demonstrable urban trial conversion ≥8% before national rollout.
• For mens vitality supplements, focus on regulatory clearance and channel partnerships; reallocate incremental marketing only if share expands to ≥5% within 24 months.

Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - BCG Matrix Analysis: Dogs

The following section addresses the 'Dogs' category within Dong-E-E-Jiao's portfolio, focusing on underperforming legacy and peripheral businesses that exhibit low market growth and low relative market share as of 2025. These units drain resources and are candidates for divestment, outsourcing, or phased withdrawal.

Summary table of key metrics for each Dog segment:

Legacy non-Ejiao generic TCM

The legacy generic TCM segment contributes 3.8% to consolidated revenue in 2025, with market growth of only 1.2% and gross margins compressed to 26%, materially below the corporate average (company average gross margin ~38%). Relative market share is below 2% in the TCM market, and price competition has eroded pricing power. CAPEX for the segment has been set to 0% to preserve capital for high-return Ejiao+ initiatives. Operational indicators: inventory turnover declined to 3.5x (2025) from 4.2x (2022); SKU rationalization reduced SKUs by 28% in 2024, yielding limited cost relief.

• Revenue share: 3.8%
• Gross margin: 26%
• Market share: <2%
• CAPEX: 0%

Agricultural donkey breeding services

The donkey-breeding division secures supply chain control for raw materials (ejiao) but accounts for only 2.0% of revenue. Market growth is 1.0% with high operating expenditures (feed, veterinary, labor), producing an ROI of approximately 4% and often near break-even net profit after overhead allocation. Market share is under 5% in commercial breeding where fragmented smallholders dominate. Current capital tied up is roughly 6% of historical CAPEX; management is evaluating outsourcing or contract farming to reduce fixed-asset intensity and lower working capital needs.

• Revenue share: 2.0%
• ROI: ~4%
• Market share: <5%
• CAPEX tied up: ~6%

Regional low-end medicinal liquors

Low-end medicinal liquor SKUs contribute 1.0% of group revenue and are impacted by a -3.0% annual decline in urban demand as consumers favor premium health beverages. Gross margin has fallen to 22%, and distribution overheads push the segment into negative ROI territory once channel costs are included. Market share is roughly 1%. No CAPEX has been allocated for three consecutive years, and the segment is undergoing SKU pruning and selective regional withdrawal.

• Revenue share: 1.0%
• Market growth: -3.0%
• Gross margin: 22%
• CAPEX: 0% (3 years)

Discontinued seasonal health gift boxes

Generic seasonal gift boxes now represent 1.4% of revenue and face a -5.0% market decline as gifting moves to personalization and digital alternatives. Gross margins are weak at 20% due to packaging and clearance discounting; ROI is ~2%. Market share in the generic gift category has fallen below 2%. The company has redirected the former 4% of CAPEX to develop Ejiao+ premium and branded gift offerings; remaining inventories are being cleared through promotional channels.

• Revenue share: 1.4%
• Market growth: -5.0%
• Gross margin: 20%
• Prior CAPEX reallocated: 4%